Product Description
Ref-SKU:
014V-02134 Pasteur Virus (PV) vaccine strain, passage 12, BSR adapted, infectivity quantified
Product Risk Group:
ICTV Taxonomy:
Virus name:
Strain:
Isolate:
Storage conditions:
Viral Storage Medium -80C
Sequencing:
Complete genome
Infectivity:
Infectivity tested and quantified
Mycoplasmic content:
Mycoplasma free
Special feature:
GMO:
No
Biosafety restrictions:
BSL3
Virus host type:
Infectivity Test:
Detection of Fluorescence Focus Units in BSR cell-line
Production cell line:
Virus Cultivability:
Passage:
12 original passages (1976), 1 amplification on suckling mice (2005), 6 passages in BSR cells (2010)
Shipping conditions:
IATA Classification:
Information about the collection of the virus
Recombinant product:
No
Biological material origin:
Natural origin
Collection date:
Thursday, 1 January, 1976
Country of collection:
Suspected epidemiological origin :
Comments (1)
I am sorry, but I open new account - I have some problem with my account on EVAg.
We received Pasteur Virus (PV) vaccine strain, isolate PV12, BSR adapted
VACCINAL STRAIN by MTA with Institut Pasteur 10/02/2020 in last my order.
I will appreciate if you pay attention to the Certificate of accreditation of our campaign as a scientific research institution.Ministry of Science and Higher Education of the Republic of Kazakhstan - I added om my account as Certificate.
Certificate of accreditation of 20 May 2024
in accordance with Article 23 of the Law of the Republic of Kazakhstan on Science,
Antigen Research and Production Enterprise LLP is accredited as a subject of scientific and or scientific and technical activities for a period of 5 years. The certificate is provided for participation in competitions for scientific, scientific and technical projects and programs financed from the state budget and other sources not prohibited by the legislation of the Republic of Kazakhstan.
We have 3 grants for rabies:
1/. Project No.AP19680178 “Development of technology for the production of highly purifiedanti-rabies immunoglobulins obtained using chimeric Rabies-antigens",
Competition for grant funding for scientific and (or) scientific-technical projects for 2023-2025 (Ministry of Science and Higher EducationRepublic of Kazakhstan),
Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, 2023 - 2025, 98,985,578 tenge.
2/.Project No. AP22787122 “Development of hybrid vectors for production
polyantigen oral vaccine against rabies of wild carnivores",
Competition for grant funding for young scientists in scientific and (or) scientific-
technical projects for 2024-2026 (Ministry of Science and Higher Education
Republic of Kazakhstan), Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, 2024 - 2026, 89 925 50 tenge.
3/.IRN AP14870256 “Development of new nanobodies for effective neutralization and use as a specific and sensitive reagent for the rapid detection of rabies virus.”
Head: Bisenbaev A.K. 2023–2025 (30 months) Ministry of Education and Science of the Republic of Kazakhstan Grant financing, life and health services
I will appreciate for yours comments!
Best regards, Saule